Bcl-6

Inhibitory Selectivity

Bcl-6 Products

Catalog No. Information Product Use Citations Product Validations
S8250

79-6 (CID5721353)

79-6 (CID5721353) is a BCL6 inhibitor with Kd value of 138 μM.

S8735

BI-3812

BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.

S8591

FX1

FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis.

S6937New

BI-3802

BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor activity.

Catalog No. Information Product Use Citations Product Validations
S8250

79-6 (CID5721353)

79-6 (CID5721353) is a BCL6 inhibitor with Kd value of 138 μM.

S8735

BI-3812

BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.

S8591

FX1

FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis.

S6937New

BI-3802

BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor activity.

Tags: Bcl-6 Apoptosis | Bcl-6 Immunity | Bcl-6 Inflammatory response | Bcll-6 Transcription | Bcl-6 regulation | Bcl-6 Inhibiton